Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Presentation VIVA 2017

What is the Right Antiplatelet Therapy for Symptomatic Carotid Disease?

Presenter: William Gray

September 21, 2017

Presentation VIVA 2017

Results from the ENGAGE Registry

Presenter: Marc Schermerhorn

September 21, 2017

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Conference News VIVA 2017

ACT I: Women Reap More Long-term Benefits From Carotid Stenting vs CEA

L.A. McKeown

September 15, 2017

Presentation VIVA 2017

Results from the IN.PACT SFA Randomized Trial

Presenter: Peter A. Schneider

September 15, 2017

Presentation VIVA 2017

Two-year Results from the IN.PACT Global Study

Presenter: Thomas Zeller

September 14, 2017

Presentation VIVA 2017

Paclitaxel-Eluting Stent Treatment for PAD: Insights from the Zilver PTX Post-Market Study in Japan

Presenter: Michael Dake

September 14, 2017

News Conference News VIVA 2017

EVAR Outcomes Equivalent Between Men and Women, Registries Show

L.A. McKeown

September 14, 2017

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

L.A. McKeown

September 11, 2017

Presentation VIVA 2017

ILLUMENATE European Randomized Trial: 2-Year Results

Presenter: Marianne Brodmann

September 11, 2017

Presentation VIVA 2017

Radiation Safety: How to Protect Yourself and the Patient

Presenter: Konstantinos Katsanos

September 11, 2017

Conference VIVA 2017

VIVA 2017

Las Vegas, NV

September 11, 2017

September 14, 2017

Advertisement

What is the Right Antiplatelet Therapy for Symptomatic Carotid Disease?

Results from the ENGAGE Registry

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

ACT I: Women Reap More Long-term Benefits From Carotid Stenting vs CEA

Results from the IN.PACT SFA Randomized Trial

Two-year Results from the IN.PACT Global Study

Paclitaxel-Eluting Stent Treatment for PAD: Insights from the Zilver PTX Post-Market Study in Japan

EVAR Outcomes Equivalent Between Men and Women, Registries Show

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

ILLUMENATE European Randomized Trial: 2-Year Results

Radiation Safety: How to Protect Yourself and the Patient

VIVA 2017

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content